Hardman Monthly May 2016: Brexit — Assessing the Risks
Nigel Hawkins is again our feature writer of the month. Last month it was a review of the UK/ EU Electricity Sector – this time he has again turned his attentions to UK/EU Relations by assessing the risks to the UK financial and business sectors from our possible exit from the EU. The main conclusions from Nigel’s analysis are:► The £ Sterling will be volatile, especially if Brexit prevails.
â–º Few of the largest FTSE 100 stocks are heavily exposed to the EU- Vodafone being a notable exception.
► A vote for Brexit may be the start of a long drawn out process of exiting the EU – if the UK Parliament approves the relevant legislation.
â–º Major changes in the tariff rates would have a significant impact but existing trade arrangements may last for many years.
Allergy Therapeutics is a pharmaceutical group focused on allergy vaccination. Co. mainly sell its products in European countries and its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, as well as a peanut allergy vaccine in preclinical development. Co. sells a range of aluminium-free allergy vaccines and diagnostics. Co. sells both injectable and sublingual (oral) formats. The commonly prescribed are those for the treatment of pollen related allergies, particularly for allergies to grasses, weeds and trees. Co.'s vaccines trade under various brand names depending on the market, e.g. Pollinex Quattro, Polligoid and TA Graser Top.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.